NK cell therapy

Unknown Manufacturer

Generate AI report

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIK AND THERAPY
- EP 2287195 B1
  Applicant: NOVO NORDISK ASPriority: 2004
  CN
  EP
  US
  13 publications
- CN 1852924 A
  Applicant: INNATE PHARMAPriority: 2003
  CN
TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
EP 3687555 A4Applicant: OHIO STATE INNOVATION FOUNDATIONPriority: 2017
CN
EP
US
WO
5 publications
METHODS AND USES OF USING ACTIVATORS OF NRF2 TO ENHANCE NATURAL KILLER CELLS AND/OR T CELL ACTIVITY AND/OR SURVIVAL
EP 4373477 A2Applicant: PROLEUKOCYTE ABPriority: 2021
CN
EP
US
WO
5 publications
NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
EP 3565565 A4Applicant: UNIV NOVA SOUTHEASTERNPriority: 2017
EP
US
WO
5 publications
PDL1 POSITIVE NK CELL CANCER TREATMENT
EP 3989984 A4Applicant: HOPE CITYPriority: 2019
CN
EP
US
WO
4 publications
CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO B-CELL MATURE ANTIGEN (BCMA) AND/OR TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR (TACI)
EP 4590329 A2Applicant: ELPIS BIOPHARMACEUTICALSPriority: 2022
CN
EP
US
WO
4 publications
IMPROVED NK-BASED CELL THERAPY
EP 3551294 A1Applicant: ONKIMMUNE LTDPriority: 2016
CN
EP
US
4 publications
PURIFYING TCR-MODIFIED T CELLS USING TCR-SPECIFIC CAR-NK CELLS
US 20260130994 A1Applicant: UNIV BERLIN CHARITEPriority: 2022
EP
US
WO
4 publications
COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLS
US 2021338723 A1Applicant: UNIV WASHINGTONPriority: 2020
US
WO
4 publications
Compositions and methods for regulating NK cell activity
US 2006280740 A1Applicant: NOVO NORDISK ASPriority: 2006
US
4 publications

Drugs

NK cell therapy

Patents

PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIK AND THERAPY